Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report

RATIONALE: Anti-CD19-targeted chimeric antigen receptor (CAR) T cell therapy is effective in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This therapy is associated with several side effects that can be life-threatening such as cytokine release syndrome (CRS). However, chyloth...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hsin-Hui, Kuo, Cheng-Yi, Ho, Ching-Liang, Chen, Yeu-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578660/
https://www.ncbi.nlm.nih.gov/pubmed/37832125
http://dx.doi.org/10.1097/MD.0000000000035432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578660/
https://www.ncbi.nlm.nih.gov/pubmed/37832125
http://dx.doi.org/10.1097/MD.0000000000035432

Ejemplares similares